IL322678A - MC2R modulator compounds - Google Patents
MC2R modulator compoundsInfo
- Publication number
- IL322678A IL322678A IL322678A IL32267825A IL322678A IL 322678 A IL322678 A IL 322678A IL 322678 A IL322678 A IL 322678A IL 32267825 A IL32267825 A IL 32267825A IL 322678 A IL322678 A IL 322678A
- Authority
- IL
- Israel
- Prior art keywords
- piperidine
- spiro
- naphthyridine
- optionally substituted
- trifluoromethyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/20—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2302630.5A GB202302630D0 (en) | 2023-02-23 | 2023-02-23 | Mc2r modulator compounds |
| GBGB2308196.1A GB202308196D0 (en) | 2023-06-01 | 2023-06-01 | Mc2r Modulator compounds |
| GBGB2313601.3A GB202313601D0 (en) | 2023-09-06 | 2023-09-06 | MC2R modulator compounds |
| GBGB2319945.8A GB202319945D0 (en) | 2023-12-22 | 2023-12-22 | MC2R modulator compounds |
| PCT/GB2024/050502 WO2024175928A1 (en) | 2023-02-23 | 2024-02-23 | Mc2r modulator compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL322678A true IL322678A (en) | 2025-10-01 |
Family
ID=90362427
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL322678A IL322678A (en) | 2023-02-23 | 2024-02-23 | MC2R modulator compounds |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP4669646A1 (de) |
| JP (1) | JP2026507093A (de) |
| KR (1) | KR20250151442A (de) |
| CN (1) | CN121002019A (de) |
| AU (1) | AU2024225939A1 (de) |
| IL (1) | IL322678A (de) |
| MX (1) | MX2025009912A (de) |
| WO (1) | WO2024175928A1 (de) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB202004961D0 (en) | 2020-04-03 | 2020-05-20 | Micromass Ltd | De-clustering guide |
| GB202412595D0 (en) | 2024-08-28 | 2024-10-09 | Omass Therapeutics Ltd | Mc2r modulator compounds |
| WO2026047337A1 (en) | 2024-08-28 | 2026-03-05 | Omass Therapeutics Limited | Mc2r modulator compounds |
| WO2026047334A1 (en) | 2024-08-28 | 2026-03-05 | Omass Therapeutics Limited | Mc2r modulator compounds |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1768041A (zh) * | 2003-04-04 | 2006-05-03 | 麦克公司 | 作为黑皮质素－4受体激动剂的酰化螺哌啶衍生物 |
| US10684416B2 (en) | 2017-07-27 | 2020-06-16 | Ii-Vi Delaware Inc. | Fabrication-tolerant and broadband polarization splitter and rotator |
| US12479825B2 (en) | 2019-11-07 | 2025-11-25 | Crinetics Pharmaceuticals, Inc. | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof |
| CA3164117A1 (en) | 2019-12-18 | 2021-06-24 | Crinetics Pharmaceuticals, Inc. | Gem-disubstituted piperidine melanocortin subtype-2 receptor (mc2r) antagonists and uses thereof |
| ES3032933T3 (en) | 2019-12-23 | 2025-07-29 | Crinetics Pharmaceuticals Inc | Spirocyclic piperidine melanocortin subtype-2 receptor (mc2r) antagonists and uses thereof |
-
2024
- 2024-02-23 EP EP24710165.2A patent/EP4669646A1/de active Pending
- 2024-02-23 KR KR1020257030624A patent/KR20250151442A/ko active Pending
- 2024-02-23 JP JP2025549749A patent/JP2026507093A/ja active Pending
- 2024-02-23 WO PCT/GB2024/050502 patent/WO2024175928A1/en not_active Ceased
- 2024-02-23 CN CN202480025390.XA patent/CN121002019A/zh active Pending
- 2024-02-23 IL IL322678A patent/IL322678A/en unknown
- 2024-02-23 AU AU2024225939A patent/AU2024225939A1/en active Pending
-
2025
- 2025-08-21 MX MX2025009912A patent/MX2025009912A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN121002019A (zh) | 2025-11-21 |
| EP4669646A1 (de) | 2025-12-31 |
| MX2025009912A (es) | 2025-10-01 |
| AU2024225939A1 (en) | 2025-08-21 |
| KR20250151442A (ko) | 2025-10-21 |
| WO2024175928A1 (en) | 2024-08-29 |
| JP2026507093A (ja) | 2026-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3601239B1 (de) | Neuartige, als shp2-inhibitoren nützliche heterocyclische derivate | |
| IL322678A (en) | MC2R modulator compounds | |
| WO2024238633A2 (en) | Kras g12s and g12c inhibitors | |
| CA3228310A1 (en) | Heterocyclic compounds and methods of use | |
| CA2903875C (en) | 6-(5-hydroxy-1h-pyrazol-1-yl)nicotinamide derivatives and their use as phd inhibitors | |
| WO2022266258A1 (en) | Compounds and methods for the targeted degradation of irak-4 | |
| KR20210014108A (ko) | Parp7 억제제로서의 피리다지논 | |
| CA2837883C (en) | Metabotropic glutamate receptor 5 modulators and methods of use thereof | |
| CN116003321A (zh) | 可用作shp2抑制剂的新型杂环衍生物 | |
| CA2973760A1 (en) | Pyrazine compounds for the treatment of infectious diseases | |
| JP2026503032A (ja) | Ｓｈｐ２阻害剤及びその使用 | |
| WO2021048200A1 (en) | Novel quinoline compounds for the treatment of autoimmune disease | |
| EP3390404B1 (de) | Tricyclische verbindungen und zusammensetzungen als kinasehemmer | |
| WO2025136898A1 (en) | Agonists of trem2 activity | |
| IL325053A (en) | WRN inhibitors | |
| KR20230035437A (ko) | 7-치환된 1-아릴-나프티리딘-3-카르복실산 아미드 및 그의 용도 | |
| CA3104955A1 (en) | Tyrosine amide derivatives as rho- kinase inhibitors | |
| WO2024175925A1 (en) | Mc2r modulator compounds | |
| AU2024272375A1 (en) | Substituted quinoxalines | |
| WO2024059558A1 (en) | Polycyclic quinazolines for inhibition of erbb2 | |
| TW202417421A (zh) | 作為ｊａｋ２抑制劑之雜環醯胺及脲化合物 | |
| WO2025231261A1 (en) | Bicyclic and heterocyclic amide compounds | |
| WO2026047575A1 (en) | Hydroquinazoline derivatives for the treatment of a disease or disorder | |
| WO2025194599A1 (en) | Heterocycle ulk1/2 inhibitors and methods of use thereof | |
| HK40041802A (en) | Novel pyrrolidinyl amide compounds for the treatment of autoimmune disease |